Accenture and Oracle Enhance the Accenture Life Sciences Cloud for R&D with the Introduction of an End-to-End Clinical Data Management Capability
NEW YORK; Apr. 22, 2015 – Accenture (NYSE: ACN) has expanded the
This latest version of the Accenture Life Sciences Cloud for R&D offers the Oracle Health Sciences Data Management Workbench (DMW), which includes prebuilt integrations to the Oracle Health Sciences InForm, an electronic data capture (EDC) solution to create an end-to-end clinical data collection and management platform.
With the addition of the Oracle Health Sciences DMW, the Accenture Life Sciences Cloud for R&D automates the time-consuming and resource-intensive manual processes required to load, transform and clean trial data. Trial sponsors and contract research organizations will now be able to increase the speed and accuracy of data collection, integration and analysis; achieve greater efficiency of clinical workflow and query management; and accelerate stakeholders’ access to data across the trial lifecycle from source to submission.
The Oracle Health Sciences DMW provides the Accenture Life Sciences Cloud for R&D with several key benefits, including:
- Optimized clinical data management through reusable workflows for easier global clinical trial setup and implementation;
- Simplified integration with disparate data providers such as CROs and central labs;
- Improved submissions by more quickly delivering clean, structure-ready and validated data for biostatistical analysis; and
- More-efficient clinical operations, with advanced mechanisms facilitating operational re-use to streamline cleansing and transformations based on industry standards.
Additionally, the Oracle Health Sciences DMW in the Accenture Life Sciences Cloud for R&D is pre-integrated with the Oracle Health Sciences InForm EDC platform. The latest release of InForm, version 6.1, enables fully integrated capabilities including coding and IRT, rapid and reliable trial builds, and one-click, self-service deployment, including mid-study changes. As a result, life sciences organizations gain a seamless flow of data, from electronic data capture to data management to analysis.
“Being able to take advantage of new technologies for clinical data management in combination with Oracle InForm is a key factor to helping our clients bring life-improving medicines to patients faster,” said Kevin Julian, managing director of Accelerated R&D Services, Accenture Life Sciences. “This latest version of Accenture Life Sciences Cloud for R&D harnesses the highly differentiated capabilities of a pre-integrated end-to-end clinical R&D platform based on leading technology from Oracle.”
The combined solution from Accenture – a Diamond-level member of Oracle PartnerNetwork - and Oracle bring together Oracle’s experience in developing and hosting mission-critical clinical data warehousing and analytics applications for life sciences with Accenture’s proven implementation capabilities to deliver service-based solutions.
“As the industry’s only true end-to-end data management solution in a single environment, Oracle Health Sciences Data Management Workbench accelerates the speed and accuracy of clinical data integration, reconciliation, aggregation, and analysis by reducing time -consuming manual processes required to load, transform, and clean trial data. Accenture’s Life Sciences Cloud for R&D with Data Management Workbench is changing the way technology is developed and delivered across the life sciences industry, helping life sciences organizations provide life-improving therapies faster and at a lower cost,” said Steve Rosenberg, general manager of Oracle’s Health Sciences Global Business Unit. “We at Oracle are proud that our industry-leading cloud solutions are at the heart of this leading capability.”
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- How the NIMBLE Study Supported Adherence With Quarterly Dosing of Cemdisiran
September 18th 2025
- Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025
- IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
September 17th 2025
- Managing Background Therapies in the NIMBLE Phase III Trial
September 17th 2025